3′,6-substituted indirubins and their biological applications

1. An indirubin derivative of formula I

wherein

R represents -(A) n - R 1 or —CO—N(R 2 ,R 3 ) with

A being C1-C5 alkylene group, optionally substituted by one or several A 1 radical, A 1 being an halogen Br, OH, OR 4 or NH 2 , R 4 being C1-C5 alkyl;

R 1 being halogen, OH, N(R 2 , R 3 ); R 2 and R 3 , identical or different, being C1-C5 alkyl, optionally substituted by A 1 such as above defined, or R 2 and R 3 are part of a cycle with 5 or 6 elements optionally comprising another heteroatom such as O or N;

n=1-5,

with the exclusion of 2H-indol-2-one, 6-bromo-3-[(3E)-1,3-dihydro-3-[[2-(1-pyrrolidinyl)ethoxy]imino]-2H-indol-2-ylidene]˜1,3-dihydro- , (3Z).

2. A pharmaceutically acceptable salt of an indirubin derivative of claim 1 .

3. The indirubin derivative of claim 1 , wherein R represents-(A) n -R 1 , with R 1 being halogen, OH, N(R 2 , R 3 ) and R 2 and R 3 , identical or different, are C1-C5 alkyl, optionally substituted by A 1 such as above defined.

4. The indirubin derivative of claim 3 , wherein R 1 is Br or OH and A represents a —(CH 2 ) m1 —CH (R 1 )—(CH 2 ) m2 radical, wherein m 1 =1-3 and m 2 =0, 1-3.

5. The indirubin derivative of claim 3 , wherein R 1 is N (R 2 , R 3 ).

6. The indirubin derivative of claim 1 , wherein A is C1-C5 alkylene group.

7. The indirubin derivative of claim 1 , wherein R represents —CO—N (R 2 ,R 3 ), with R 2 and R 3 , identical or different, being a C1-C5 alkyl radical.

8. A pharmaceutical composition comprising a therapeutically effective amount of at least one indirubin derivative of claim 1 , in association with a pharmaceutically acceptable vehicle.

9. The pharmaceutical composition of claim 8 , wherein the at least one indirubin derivative is in a form suitable for an administration by intravenous route or intramuscular or subcutaneous.